BioRem Inc. (BRM) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of BioRem Inc. stock C$5.54, price C$4.20, upside +31.9%, quality 75 out of 100. Rating: undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.
How to read this chart
60‑month range C$0.4300 – C$4.44 · fair‑value band C$4.12 – C$7.09 · the C$4.20 price screens below the C$5.54 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 7, 2026.
Follow BioRem in your weekly email
Every Wednesday you see whether BioRem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
BioRem Inc., a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds, and hazardous air pollutants.
Show moreShow less
The company offers biofilters; biotrickling filters; multi-stage systems; biogas desulfurization systems; dry scrubber adsorption systems; and cannabis odor control systems. It also sells biofiltration media products under the BIOSORBENS, XLD, BIOPAK, BIOROLL, and BIOBLOK names.
The company operates in Canada, the United States, China, and internationally.
In addition, its products are used in wastewater and water treatment plants, municipal solid waste and waste to energy, pet food manufacturing, rendering plants, food and beverage, petrochemical, semiconductor, chemical production facilities industries.
BioRem Inc. was founded in 1990 and is headquartered in Puslinch, Canada.
Stock analysis
BioRem Inc. (BRM) currently trades at C$4.20, while our model-based Fair Value estimate is C$5.54, implying the stock looks roughly 24% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of C$8.39 per share, and 19 of the 24 models we run sit above the C$4.20 price.
Bear case: the Asset-Based group reads lowest at C$0.7300, and 5 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: C$4.12 (bear) to C$7.09 (bull), the price of C$4.20 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 75/100 (high quality), in the Industrials sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
BioRem Inc. reported revenue of C$42.4M in FY2025 versus C$24.5M in FY2021, a compound +14.7%/yr. Reported net income was C$4.8M in FY2025, compounding +38.8%/yr from FY2021.
Key figures
Market cap C$67.8M (≈ $48.0M) Micro · P/E ratio 12.7 · P/S ratio 1.34 · EPS (TTM) C$0.3300 · Net margin 12.3% · Return on equity 43.6% · Return on assets (EBIT) 14.3% (5-year average) · Operating margin 17.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 74 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 95% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 3% fair-value upside, at 32%, BRM screens cheaper than that median.
Fair Value models
BearC$4.12Fair Value C$5.54BullC$7.09
Price C$4.20 · Upside +31.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (C$0.2830 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.87/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+13.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.7%
Start year 2020 (pandemic). Over 10 years: +9.6% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+48.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+48.1%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.46.8% vs 24.9%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.11% → 16%
2025 sits 134% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−4.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about −6.6% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pollution & Treatment Controls · 86 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "BioRem Inc. Fair Value". https://www.fairvalue-calculator.com/stock/BRM
Frequently asked questions
Is BioRem Inc. (BRM) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of C$5.54 versus a price of C$4.20, about +32% upside (undervalued).
What is the fair value of BRM?
Our model-based fair value for BioRem Inc. is C$5.54 (as of Nov 7, 2026), built from audited fundamentals. The current price: C$4.20.
What is the quality score of BRM?
BioRem Inc. has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioRem Inc. (BRM)?
Our model-based price target is the fair value of C$5.54 (as of Nov 7, 2026) from 24 valuation models. Cautious scenario C$4.12, optimistic scenario C$7.09. It is a calculation from audited fundamentals, not an analyst target.
What is the BioRem Inc. stock forecast for 2026?
Our models put fair value at C$5.54, about +32% upside versus a price of C$4.20 (undervalued). Cautious scenario C$4.12, optimistic scenario C$7.09. The calculation is refreshed regularly with new filings.
What is the revenue of BioRem Inc. (BRM)?
BioRem Inc. reported trailing-twelve-month revenue of about C$50.7M (latest available figure, as of Nov 7, 2026).
What growth is priced into BioRem Inc. (BRM)?
For today's price to be fair in a discounted-cash-flow model, BioRem Inc. would have to grow free cash flow by -4.7 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.7 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of BRM use?
Our models discount BioRem Inc. at 9.6 %: a base by market capitalisation (nano), damped by beta 1.04, country premium for Canada. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioRem Inc. that is -4.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has BioRem Inc. (BRM) delivered so far?
Over the past 5 years revenue at BioRem Inc. grew +11.7 % a year. The price currently implies free-cash-flow growth of -4.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioRem Inc. (BRM) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into BioRem Inc. (-4.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioRem Inc. (BRM)?
The free-cash-flow yield on the price is 10.73 %: that much free cash flow BioRem Inc. produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioRem Inc. (BRM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioRem Inc. it is C$5.54 per share (as of Nov 7, 2026), against a price of C$4.20. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is BioRem Inc. stock overvalued or undervalued in 2026?
As of Nov 7, 2026, BRM trades below its calculated fair value: price C$4.20, fair value C$5.54, a gap of about +32% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRM?
No. The price is what the market pays today (C$4.20); the fair value is what the company's own numbers justify (C$5.54). For BioRem Inc. the two are C$1.34 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioRem Inc. worth?
The market values BioRem Inc. at about C$67.8M (market capitalisation, as of Nov 7, 2026). Per share that is C$4.20; our models calculate a fair value of C$5.54 per share.
What do the bullish and bearish scenarios say about BRM?
Our models span a range for BioRem Inc.: cautious scenario C$4.12, base C$5.54, optimistic C$7.09 per share (as of Nov 7, 2026, price C$4.20). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BRM?
BioRem Inc. trades at a price-to-earnings ratio of 12.7 (as of Nov 7, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of C$5.54 is built from several models across several years. Median P/E at fiscal year-end, 9 fiscal years (2016 to 2025), reported earnings: 10.2. Other multiples: P/B 4.5, P/S 1.3, EV/EBITDA 6.7.
How solid is the balance sheet of BioRem Inc. (BRM)?
Balance-sheet figures for BioRem Inc. (as of Nov 7, 2026): return on equity 43.6%, debt of 0.09 per unit of equity. They feed the Quality Score of 75/100, which measures business quality independently of the share price.
How far is BRM from its 52-week high?
BioRem Inc. trades at C$4.20, about 5% below its 52-week high of C$4.44 and 95% above the low of C$2.15 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of C$5.54 is for.
Which stocks are comparable to BioRem Inc.?
From the same area (Industrials) we also value Veralto Corporation, Zurn Elkay Water Solutions Corporation, Fujian Longking Co, Munters Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioRem Inc. stock attractive at the current price?
The data as of Nov 7, 2026: price C$4.20, calculated fair value C$5.54 (+32%), Quality Score 75/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRM calculated?
We run BioRem Inc. through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of C$5.54 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BioRem Inc. currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioRem Inc. (BRM)?
The closing price on Nov 6, 2026 was C$4.20. Our model-based fair value is C$5.54, about +32% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioRem Inc. right now?
The rarer combination: high quality (75/100) AND below fair value. That earns a closer look rather than a quick verdict. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of BioRem Inc.
How large is the market capitalisation of BioRem Inc. (BRM)?
The market capitalisation of BioRem Inc. is C$67.8M (≈ $48.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioRem Inc. (BRM)?
The price-to-sales ratio of BioRem Inc. is 1.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioRem Inc. (BRM)?
Earnings per share at BioRem Inc. are C$0.3300 (price ÷ EPS = P/E 12.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioRem Inc. (BRM)?
The net margin of BioRem Inc. is 12.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioRem Inc. (BRM)?
The return on equity (ROE) of BioRem Inc. is 43.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioRem Inc. (BRM)?
On an EBIT basis the return on assets of BioRem Inc. is 14.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioRem Inc. (BRM)?
The operating margin of BioRem Inc. is 17.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioRem Inc. (BRM)?
Revenue at BioRem Inc. is growing +66.4% versus a year earlier (3y avg +13.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioRem Inc. (BRM)?
Earnings per share at BioRem Inc. are growing +163% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does BioRem Inc. (BRM) carry?
The net debt of BioRem Inc. is C$1.9M (fiscal year 2023, ≈ 0.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioRem Inc. in the live analysis
One click puts BioRem Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 7, 2026